Professor Rachel Klevit – University of Washington

01/02/2024 9:30 am - 01/02/2024 10:30 am
Davis Auditorium

WEHI Special Ubiquitin Signalling Seminar hosted by Dr Bernhard Lechtenberg

Professor Rachel Klevit
Edmond H. Fischer/Washington Research Foundation Endowed Chair in Biochemistry | Professor of Biochemistry, Adjunct Professor of Chemistry, University of Washington


BRCA1/BARD1 30 years on: What we know and what we still don’t know


Davis Auditorium

Join via TEAMS

Including Q&A session


Rachel Klevit was among the first female Rhodes Scholars, attending Oxford University where she received a D. Phil.in Chemistry. Following post-doctoral training at Duke University, she joined the faculty at University of Washington. An early pioneer in protein NMR, she uses biochemical, biophysical, and structural approaches to address fundamental questions in biology. Her studies established many of the current paradigms in the Ubiquitin field. Recently, the Klevit lab defined a concept dubbed “quasi-order” to describe small heat shock proteins, chaperones that contain substantial intrinsic disorder themselves. Prof. Klevit holds the Edmond H Fischer/WRF Endowed Chair in Biochemistry and is a member of the National Academy of Sciences and the American Academy of Arts & Sciences.


BRCA1, the first gene associated with high risk for breast cancer, was discovered 30 years ago and was found to be a Ubiquitin E3 ligase almost 25 years ago. BARD1, the protein product of what is now known as a “sister gene” of BRCA1, forms an obligate heterodimeric complex with BRCA1 through its RING domain. Despite a preponderance of inherited disease-associated mutations in both BRCA1 and BARD1 RING domains, a role for the Ubiquitin E3 ligase function in tumor suppression remains both enigmatic and controversial. I will present a historical perspective, recent findings, and the current state of knowledge for BRCA1/BARD1 and will highlight what remains to be understood about the complex now known to increase risk for ovarian cancer and certain aggressive types of prostate cancer as well as breast cancer.


All welcome!

Support us

Together we can create a brighter future

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Summer 2023
View the current issue